Similarly, 2 reports by Liu et al[27] and Sheng et al[28] suggested that NSCLC patients with EGFR exon 19 deletion had a longer PFS and OS, and a higher response rate after EGFR-TKI therapy compared with those with exon 21 L858R mutation. This evidence concerns the gene EGFR and non-small cell lung carcinoma.